Last Updated: 12 January 2025
In a bold move that could reshape the landscape of oncology research, N-Power Medicine has acquired Syapse Holdings Inc., a precision medicine innovator known for its work with community cancer centers.
This partnership brings together Syapse’s extensive network of over 1,000 oncologists, cutting-edge technology, and an experienced team to create the largest community-based clinical research network in the U.S.
Community care is where over 80% of cancer patients in the U.S. receive treatment. Many of these patients, especially those from diverse and underserved populations, face barriers to accessing clinical trials. This acquisition directly addresses that challenge, making it easier for every patient to be part of potentially life-saving research, seamlessly integrated into their routine care.
"The integration of Syapse into N-Power underscores our commitment to dramatically accelerating drug development and improving the probability of success by seamlessly integrating clinical research into every oncologist’s practice and every cancer patient’s care. With this scale, N-Power accelerates the transformation of drug development that our pharma customers are asking for - enabling local access to clinical trials for more community oncologists and community cancer patients than ever before, and by creating a unique platform for generating prospective external controls, reducing the need for randomized trials."
Mark Lee, M.D., Ph.D, the Co-Founder & CEO of N-Power Medicine
For decades, clinical trials were largely confined to academic hospitals, leaving millions without access.
With this partnership, N-Power Medicine leverages Syapse’s network to bring trials closer to home. The integration of N-Power’s AI-powered Kaleido Registry with Syapse’s tools will ensure real-time, research-ready patient data is available, revolutionizing how trials are conducted.
This new approach doesn’t just help patients. It’s a win for pharmaceutical companies like Merck, which already collaborates with N-Power. By tapping into a geographically diverse patient pool, companies can run faster, smaller trials with more reliable data—potentially shaving years off the drug development process.
Finalized on December 30, 2024, this stock-for-stock transaction brings new financial support from Innovatus Capital Partners LLC, joining existing investors like the Merck Global Health Innovation Fund. Backed by these stakeholders, N-Power Medicine is poised to lead the next era of oncology research—one where trials are faster, more inclusive, and rooted in real-world patient care.
“Syapse joining N-Power represents a transformative step forward in our shared mission to revolutionize community-based patient care. By building upon Syapse’s existing offerings for its health system and pharma partners with N-Power’s AI-enabled ‘human-in-the-loop’ approach, we can significantly expand access to prospective clinical trials and life-saving innovations for patients in community settings. We are proud to join N-Power in building a future where community oncology serves as a powerful catalyst for research and improved patient outcomes.”
Michael Mentesana, CEO of Syapse
